- Health Canada has approved VUEWAY (gadopiclenol) by Bracco Imaging for contrast-enhanced MRI in adults and children aged ≥2 years
- VUEWAY is a macrocyclic gadolinium-based contrast agent designed to deliver effective imaging at half the standard gadolinium dose (0.05 mmol/kg), helping reduce patient exposure
- The agent is indicated for CNS and whole-body CE-MRI, including imaging of the brain, spine, liver, kidneys, breast, pelvis, and musculoskeletal system
- Already approved in the U.S. and EU, VUEWAY has been used in >4M patient doses globally and supports growing efforts to improve patient safety and reduce environmental impact linked to gadolinium exposure
Takeaways
VUEWAY should help Bracco win share in Canada’s MRI contrast market by offering radiology departments a lower‑gadolinium option that still delivers high‑quality images, which is increasingly attractive for hospitals focused on safety and sustainability metrics.
Because it can be used broadly across CNS and whole‑body MRI at half the standard gadolinium dose and already has a track record of more than 4 million doses worldwide, VUEWAY is likely to be favored in tenders and protocol updates, putting competitive pressure on older macrocyclic agents that lack a clear dose‑reduction story.
Source: PRnewswire
